FloBiotech Signs Agreement with UCLA Health to Advance Neurodegenerative Disease Treatments
Wednesday, June 10, 2026
FloBiotech has entered into an agreement with UCLA Health to support the development of a new class of therapies for neurodegenerative diseases by targeting protective biological pathways involved in disease progression.
As part of the agreement, FloBiotech has secured a licence for DDL-357, an advanced small-molecule therapy developed at UCLA Health. Preclinical data showed that the compound increased brain clusterin levels, reduced phosphorylated tau by around 40%, and improved memory performance in disease models, highlighting its potential as a disease-modifying treatment.
Neurodegenerative diseases affect more than 55 million people worldwide and remain one of the largest areas of unmet medical need. Many existing treatment approaches focus on blocking disease-related processes after symptoms appear and have shown limited impact on slowing disease progression.
FloBiotech is pursuing a different strategy by developing precision small-molecule therapies designed to act earlier in the disease process. The company’s approach aims to strengthen the brain’s natural protective mechanisms against toxic protein stress and is based on enhancing biological pathways such as clusterin biology. The platform has the potential to be applied across several neurodegenerative disorders.
The agreement builds on FloBiotech’s collaboration with Professor Varghese John and his research team at UCLA Health, whose work led to the development of DDL-357 and a broader portfolio of compounds targeting neurodegenerative disease mechanisms. In addition to supporting the advancement of DDL-357, the partnership will enable continued scientific collaboration and may lead to the development of additional therapeutic programmes.
FloBiotech is pursuing a multi-indication development strategy. Alongside its long-term focus on Alzheimer’s disease, the company is also exploring the use of DDL-357 in Progressive Supranuclear Palsy (PSP) to establish early clinical proof of mechanism.
The agreement strengthens FloBiotech’s efforts to build a pipeline of therapies aimed at addressing the underlying causes of neurodegenerative diseases and supporting both near-term clinical development and long-term growth.
Source: globenewswire.com
